Medtronic Engineering the extraordinary

# MiniMed™ 780G System

Automated Insulin Delivery Technology



For many with type 1 diabetes, mealtimes can be a challenge. Before each meal, carbohydrates (carbs) have to be calculated so you can take enough insulin to cover the carbs. If you forget to give yourself a correction dose of insulin (bolus) or miscalculate your carbs, your blood sugars can go out of range and then you're spending time - sometimes hours - bringing them back into range.

The new MiniMed™ 780G system was designed with the goal of simplifying meal management by auto-adjusting every five minutes§ to deliver both the background insulin users need 24-7 and help provide coverage for mealtime insulin.¹

This real-time adjustment is important as up to 42 factors may affect blood sugar levels on any given day including exercise, hormones, food, and medications. As a result, your insulin needs vary daily and changes in blood sugars can be unpredictable based on these factors. Other automated insulin pumps on the market adjust insulin every hour or are limited to basal insulin delivery. **Real-time matters with diabetes management because a lot can happen in an hour.** 

### **Designed for Real Life**

The MiniMed™ 780G system takes on more of the diabetes management – making adjustments early, often and continually – so people do less work to keep their sugar levels in range. This has translated into high satisfaction with ease of use and improved quality of life benefits:

- **94%** of users say they are satisfied with the impact the system has on their quality of life.<sup>2</sup>
- **93%** of users say they are satisfied with the impact the system has on their mealtimes.<sup>2</sup>
- **88%** say they are experiencing better quality sleep<sup>2</sup>
- **95%** time spent in SmartGuard™ technology³.

The system was designed to help simplify diabetes management with the following key components:

- **New Guardian<sup>™</sup> 4 Sensor:** The newest Medtronic sensor integrated with this system enables no fingersticks with SmartGuard<sup>™</sup> technology\*\*, enabling a much more seamless experience.
- **Lowest Target Rate:** The only system with flexible targets as low as 100 mg/dl.<sup>4</sup> This is the lowest glucose target available and it was designed with feedback from users who wanted a target that more closely mimics a healthy pancreas of someone not living with diabetes. The system offers more flexibility as users can now choose three different target settings based on their preference and needs.
- **Longest Wearing Infusion Set:** The MiniMed<sup>™</sup> 780G system is the only system that offers an infusion set that can be worn up to 7 days doubling the wear time of other sets on the market<sup>5</sup>. This means users can now sync their sensor and infusion set changes on the same day.



#### "This technology has given our son his childhood back." – Kristy

"Our son often felt left out from playdates or sleepovers away from home. It was heartbreaking having to say no, worrying there was too much that could go wrong when he wasn't in our care, but my job as his mom is to keep him healthy and safe. I liken it to wearing a seatbelt when driving - for us the pump is Henry's 'seatbelt' that takes care of Henry when we're not around and that's really reassuring. He got his childhood back and quite frankly saved our relationship."

Kristy was compensated for her time. Thoughts and opinions are her own. Individual results may vary.



FDA approved for individuals as young as seven with type 1 diabetes

## **Medtronic Moves Closer to a Closed Loop System**

Medtronic's goal is to develop technology that "closes the loop" for people living with type 1 diabetes. This means designing a pump that requires minimal to no interaction so that diabetes management is always in the background. The MiniMed™ 780G system moves us another step closer to this vision by providing real-time sensing of glucose levels and personalized delivery of insulin throughout the day to keep those levels in a target range for as long as possible.

- § Refers to SmartGuard™ feature. Individual results may vary
- \*\* Fingersticks required in manual mode & to enter SmartGuard™. If symptoms don't match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard™.
- 1. MiniMed™ 780G system SSED
- 2. Medtronic data on file: MiniMed™780G users survey conducted in April May 202in UK, Sweden, Italy, Netherlands and Belgium. N 789
- 3. Carlson, A.L. et al. Safety and glycemic outcomes of the MiniMed™ AHCL system in subjects with T1D. Diab Tech Ther. ahead of print <a href="http://doi.org/10.1089/dia.2021.0319">http://doi.org/10.1089/dia.2021.0319</a>
- 4. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714.
- 5. The extended wear infusion set can be worn for up to 7 days. Current infusion sets are recommended for up to 3 days of wear.

# IMPORTANT SAFETY INFORMATION: MINIMED™780G SYSTEM WITH SMARTGUARD™ TECHNOLOGY WITH GUARDIAN™ 4 SENSOR

The MiniMed™ 780Gsystem is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780Gsystem includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed<sup>™</sup> 780G system consists of the following devices: MiniMed<sup>™</sup> 780G insulin pump, the Guardian<sup>™</sup> 4 transmitter, the Guardian<sup>™</sup> 4 sensor, One-press serter, the Accu-Chek<sup>™</sup> Guide Link blood glucose meter, and the Accu-Chek<sup>™</sup> Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian<sup>™</sup> 4 sensor is intended for use with the MiniMed<sup>™</sup> 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian<sup>™</sup> 4 sensor is indicated for up to seven days of continuous use.

The Guardian<sup>TM</sup> 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed<sup>TM</sup> 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian<sup>TM</sup> 4 sensor. The Guardian<sup>TM</sup> 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian<sup>TM</sup> 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard<sup>™</sup> feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard<sup>™</sup> feature.

WARNING: Do not use the MiniMed<sup>™</sup> 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed<sup>™</sup> 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not

been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult <a href="https://www.medtronicdiabetes.com/important-safety-information#minimed-780g">https://www.medtronicdiabetes.com/important-safety-information#minimed-780g</a> and the appropriate user guide at <a href="https://www.medtronicdiabetes.com/download-library">https://www.medtronicdiabetes.com/download-library</a>

US-IPT-2300146 © 2023 Medtronic. All rights reserved. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Accu-Chek® and Accu-Chek® GUIDE LINK are trademarks of Roche Diabetes Care. DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed™780G system algorithm includes technology developed by DreaMed Diabetes